| Schedule of segment reporting |
| | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | 2025 | | 2024 | | 2025 | | 2024 | | | | (in thousands) | | (in thousands) | Revenue | | $ | 3,701 | | $ | 2,287 | | $ | 10,530 | | $ | 21,898 | Less: | | | | | | | | | | | | | Employee related expenses | | | (14,666) | | | (14,712) | | | (43,407) | | | (61,760) | Laboratory and development expenses | | | (18,675) | | | (9,028) | | | (50,235) | | | (27,508) | Professional fees | | | (4,814) | | | (1,792) | | | (9,995) | | | (6,751) | Facility expenses | | | (1,677) | | | (2,572) | | | (5,048) | | | (12,335) | Consumables | | | (750) | | | (1,439) | | | (2,383) | | | (8,123) | Other segment items(1) | | | (2,418) | | | (2,185) | | | (5,397) | | | (10,248) | Segment operating loss | | | (39,299) | | | (29,441) | | | (105,935) | | | (104,827) | Reconciliation | | | | | | | | | | | | | Depreciation and amortization expense | | | (3,632) | | | (2,986) | | | (11,789) | | | (8,285) | Share-based compensation expense | | | (3,522) | | | (3,438) | | | (13,016) | | | (17,509) | Fair value loss - contingent consideration | | | (1,823) | | | 411 | | | (5,293) | | | 2,032 | Fair value loss - liability related to pre-funded warrants | | | (5,722) | | | — | | | (5,722) | | | — | Foreign currency gains, net | | | (428) | | | 7,564 | | | 25,382 | | | 5,430 | Interest income | | | 3,503 | | | 4,866 | | | 11,154 | | | 17,179 | Interest expense - Royalty Financing Agreement | | | (13,806) | | | (12,832) | | | (40,885) | | | (37,671) | Interest expense - Hercules debt facility | | | (1,794) | | | (3,779) | | | (5,415) | | | (11,194) | Other reconciling items | | | (5,379) | | | (4,774) | | | (818) | | | (9,877) | Consolidated loss before income tax expense | | $ | (71,903) | | $ | (44,409) | | $ | (152,338) | | $ | (164,722) |
| (1) | Other segment items included in segment operating loss include costs related to intellectual property, information technology and insurance offset by income related to payments received from European authorities to subsidize the Company’s research and development in the Netherlands. |
|